

1
2
3
4
5
6
7 UNITED STATES DISTRICT COURT
8 WESTERN DISTRICT OF WASHINGTON
AT SEATTLE

9 JOHN W. BRANTIGAN,

10 Plaintiff,

11 v.

12 DEPUY SPINE, INC.,

13 Defendant.
14
15

Case No. C08-0177RSL

ORDER GRANTING IN PART AND
DENYING IN PART PLAINTIFF'S
MOTION TO COMPEL RESPONSES
TO HIS FIRST SET OF DISCOVERY

16
17 **I. INTRODUCTION**

18 This matter comes before the Court on plaintiff's motion to compel defendant to provide
19 documents and information in response to his first set of interrogatories and requests for
20 production. For the reasons set forth below, the Court grants in part and denies in part
21 plaintiff's motion.¹

22 **II. DISCUSSION**

23 Dr. John Brantigan is an orthopedic surgeon who has invented and developed devices and
24 methods to treat patients who suffer from degenerative disc disease and/or damage to
25

26 ¹ Because the Court finds that this matter can be decided on the parties' memoranda,
27 declarations, and exhibits, the parties' request for oral argument is denied.

1 intervertebral discs. Defendant is the successor in interest to a company to which plaintiff
2 assigned the rights to some of his inventions in exchange for royalties.

3 Plaintiff alleges that defendant has refused to pay him royalties owed and refused to use
4 its best efforts to market his products, despite its contractual obligation to do so. Specifically,
5 the contract requires defendant to use its “best efforts to commercialize and sell any
6 commercially viable components of the Systems.” Declaration of Katharine Saunders, (Dkt.
7 #31) (“Saunders Decl.”), Ex. 1 at ¶ 4(d). Plaintiff contends that defendant has violated this
8 provision by promoting less effective and less safe non-royalty bearing products at the expense
9 of royalty-bearing products.

10 DePuy is obligated to pay plaintiff for royalty-bearing products which include (1)
11 “System Implants,” which are the “implant device components of any of the Systems,” and (2)
12 “System Instruments,” which are the “surgical instrument components of any of the Systems.”
13 Id. at ¶ 1(g), (h). The term “System” is defined to include “any interbody fusion implant system,
14 including any and all interbody fusion implant devices and surgical instruments directly utilized
15 in connection with such implants, developed as a result of any Project, with all modifications,
16 improvements and changes that may be made in any aspect or feature of such system over time.”
17 Id. at ¶ 1(f).

18 The parties have met and conferred as required by Rule 37. However, they were unable
19 to resolve this dispute.

20 **A. Discovery on All Interbody Fusion Devices.**

21 In his discovery requests, plaintiff has sought information and documents regarding
22 defendant’s research and development of interbody fusion devices, and the safety and efficacy
23 of its interbody fusion devices, and to identify all persons who have served as project managers,
24 distributors, sales managers, principal investigators and/or regional managers for any interbody
25 fusion device. Plaintiff has defined the term “interbody fusion device” much more broadly in
26
27

1 his discovery requests than it is defined in the parties' contract.² Plaintiff's discovery definition
2 encompasses every product used to "treat vertebral, disc or spinal damage" and would require
3 defendant to disclose information and documents regarding *all* of its 8,700 parts, including
4 documents regarding defendant's research, design, development, engineering, use, testing, or
5 sampling of all of the products. Defendant argues that plaintiff is not entitled to any discovery
6 on products and devices beyond "interbody fusion devices" as that term is defined in the parties'
7 contract.

8 Plaintiff contends that he is entitled to the discovery requested to identify products for
9 which he is entitled to royalties and to determine which products are clinical substitutes for his
10 products as related to his best efforts claim. He argues that in addition to the products
11 specifically listed in the contract, he is also entitled to royalties on "[a]ll implant device
12 components ' and all 'surgical instrument components' used with those products and sold be
13 DePuy." Plaintiff's Reply at p. 2 (citing the contract at ¶ 1(f)-(h)). He claims that he cannot
14 identify those products without the discovery because some of the products could have been
15 developed without his participation or knowledge.

16 Plaintiff's requests, however, are not tailored to ascertain the universe of royalty-bearing
17 or substitute products. Instead, they seek broad categories of information that is only relevant
18 for products that actually fall into one of those two categories. For example, plaintiff seeks
19 information on the products' safety and efficacy, but that information is only relevant to
20 products that defendant allegedly promoted to the detriment of royalty-bearing products.

21 Rather than seeking broad discovery on *all* of defendant's products, plaintiff should be
22 able to identify the relevant products. He is familiar with defendant's products because he has
23 used them in his surgical practice, he was a member of defendant's advisory panel and received

24
25 ² The term "interbody fusion device" is defined in the contract to include "the I/F cages
26 covered by the Brantigan Patents, the ramps covered by the Steffee patent 5,443,514 and the
27 patent application serial no. 287.096 and other cage devices with irregular non-yielding surfaces
for facilitating bone ingrowth" Saunders Decl., Ex. 1 at ¶ 1(c).

1 regular updates about its products, and he audited defendant's records to obtain information
2 regarding allegedly unpaid royalties. He should be able to identify the devices he claims are at
3 issue based on those sources and based on whatever information he has that led him to file his
4 claims, which are subject to the standards in Rule 11. Plaintiff cannot simply allege that
5 defendant is wrongfully promoting other less safe or less effective products, then use discovery
6 to find out which products fit that description. In fact, in pre-litigation correspondence, plaintiff
7 did identify three specific products allegedly promoted at the expense of his products,
8 highlighting that it is possible to narrow his request. Declaration of Kathleen Burke, (Dkt. #42),
9 Ex. 4. Similarly, the contract specifically identifies the royalty-bearing products that existed
10 when the contract was executed. Furthermore, to the extent that plaintiff claims he lacks
11 information to identify relevant products, other avenues of discovery are available to discover
12 how the products are used rather than seeking broad categories of information regarding all of
13 defendant's products.

14 Accordingly, defendant will not be required to provide discovery on all "interbody fusion
15 devices" as plaintiff has defined that term in his discovery requests.

16 **2. Discovery Regarding Pedicle Screws.**

17 Plaintiff also alleges that defendant has refused to provide discovery regarding the design
18 and development of pedicle screws, even though he is receiving royalties for at least one pedicle
19 screw. Plaintiff argues that the documents and information are relevant to whether defendant is
20 making royalty payments on all covered devices. Defendant argues that plaintiff has been paid a
21 royalty on only one pedicle screw, which is "not a true pedicle screw" but a component of the
22 royalty-bearing Ocelot cage system. Defendant's Opposition at pp. 8-9. Although the parties
23 dispute whether plaintiff is entitled to royalties on the pedicle screws, he is entitled to conduct
24 discovery about them to determine whether they are royalty-bearing products. Plaintiff is
25 entitled to royalties on "interbody fusion devices and surgical instruments *directly utilized in*
26 *connection with such implants.*" (emphasis added). Defendant's own advertising materials
27

1 stresses that the pedicle screws and plate products “are intended for use” with some of the
2 royalty-bearing products. Declaration of William Christianson, (Dkt. #41), Ex. 2 at p. 31 (“The
3 [royalty-bearing] OCELOT Stackable Cage System is intended for use with supplemental
4 internal fixation. The supplemental internal fixation systems that may be used with the
5 Stackable Cage System include DePuy Spine titanium plate or rod systems [nine examples listed
6 including pedicle screws]”). In addition, although defendant vaguely notes that it manufactures
7 “a number” of pedicle screws, it does not identify how many or show that production would be
8 unduly burdensome. Accordingly, defendant must produce design and development information
9 regarding pedicle screws marketed during the term of the contract.

10 **3. Interrogatory No. 9.**

11 Interrogatory No. 9 seeks the date on which defendant contends the contract will expire,
12 including “the last of any ‘U.S. Patent issued in connection with any Project Inventions and/or
13 System’ [as that phrase is used in the contract] will expire and the basis for your contention.”
14 The term of the contract is a central issue in this case. Despite the obvious relevance of the
15 information sought, defendant argues that it cannot provide its response because plaintiff has not
16 identified the patent that he alleges extends the contract term until 2023. Defendant, however,
17 must provide its interpretation of the contract regardless of plaintiff’s position. Furthermore,
18 plaintiff has provided his position, albeit belatedly. Moreover, although defendant states that it
19 has no current position on the expiration date, it took a definite position in pre-litigation
20 correspondence, and despite plaintiff’s invitation, it has not disavowed that position.
21 Accordingly, defendant must provide a complete response to this interrogatory.

22 **4. Discovery Regarding the Charite Artificial Disc and Devex Products.**


23 Defendant argues that plaintiff is not entitled to royalties on the Devex family of
24 products. Defendant, however, did not address or counter plaintiff’s assertion that Devex is an
25 interbody fusion device and a potential substitute for royalty-bearing products. Information
26 regarding those products is therefore relevant to plaintiff’s best efforts claim.

1 Similarly, plaintiff argues that defendant has wrongfully withheld information on the
2 Charite device, despite admitting that it was an “alternative” to the Cougar product developed by
3 Dr. Brantigan. Saunders Decl., Ex. 13. Plaintiff contends that the information sought is relevant
4 to his claim that defendant has breached the “best efforts” clause of the contract. Although
5 defendant disputes the relevance of the documents, its conclusory statement of lack of relevance
6 has not refuted plaintiff’s best efforts contention. Accordingly, plaintiff is entitled to discovery
7 on the Devex family of products and the Charite device.

8 **III. CONCLUSION**

9 For all of the foregoing reasons, the Court GRANTS IN PART AND DENIES IN PART
10 plaintiff’s motion to compel (Dkt. #30) as set forth above. In sum, defendant must provide a
11 complete response to interrogatory no. 9 and the requested information regarding pedicle screws,
12 the Devex family of products, and the Charite device within twenty days of the date of this
13 order.

14
15 DATED this 12th day of September, 2008.

16
17 
18 Robert S. Lasnik
19 United States District Judge
20
21
22
23
24
25
26
27